Telix Pharmaceuticals Ltd
ASX:TLX

Watchlist Manager
Telix Pharmaceuticals Ltd Logo
Telix Pharmaceuticals Ltd
ASX:TLX
Watchlist
Price: 24.62 AUD -1.01% Market Closed
Market Cap: 8.2B AUD
Have any thoughts about
Telix Pharmaceuticals Ltd?
Write Note

Telix Pharmaceuticals Ltd
Operating Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Telix Pharmaceuticals Ltd
Operating Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
Telix Pharmaceuticals Ltd
ASX:TLX
Operating Income
AU$17.6m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Immutep Ltd
ASX:IMM
Operating Income
-AU$50.4m
CAGR 3-Years
-27%
CAGR 5-Years
-22%
CAGR 10-Years
-14%
Mesoblast Ltd
ASX:MSB
Operating Income
-$66.9m
CAGR 3-Years
10%
CAGR 5-Years
5%
CAGR 10-Years
N/A
CSL Ltd
ASX:CSL
Operating Income
$3.8B
CAGR 3-Years
7%
CAGR 5-Years
9%
CAGR 10-Years
9%
Clinuvel Pharmaceuticals Ltd
ASX:CUV
Operating Income
AU$57.1m
CAGR 3-Years
24%
CAGR 5-Years
27%
CAGR 10-Years
N/A
PYC Therapeutics Ltd
ASX:PYC
Operating Income
-AU$37.6m
CAGR 3-Years
-26%
CAGR 5-Years
-40%
CAGR 10-Years
-22%
No Stocks Found

Telix Pharmaceuticals Ltd
Glance View

Market Cap
8.2B AUD
Industry
Biotechnology
Economic Moat
Wide

Telix Pharmaceuticals Ltd. is an innovative biopharmaceutical company that has carved a niche for itself in the realm of targeted radiation therapy and imaging, primarily focusing on cancer treatment. Established with the vision of transforming the landscape of oncology, Telix develops molecularly-targeted radiation (MTR) products aimed at diagnosing and treating a range of significant unmet medical needs. The company's lead product, Illuccix, gained significant attention after securing regulatory approvals for use in imaging prostate cancer. Through strategic alliances with academic and research institutions, as well as commercial entities, Telix harnesses the power of radioisotopes to create compounds that bind to specific cancer cells, allowing for both precise imaging and treatment of malignancies. The business model of Telix hinges on a blend of research and development, regulatory acumen, and strategic commercialization. By advancing a pipeline of diagnostic and therapeutic radiopharmaceuticals, Telix aims to address the full cycle of cancer care—from early detection to personalized treatment. Revenue is primarily generated through the sale of its approved products, alongside potential milestone payments and royalties from partnerships. The commercial success of Illuccix and other pipeline candidates underscores the company's ability to effectively translate scientific research into marketable therapies, positioning Telix as a formidable player in the competitive arena of cancer diagnosis and treatment. By continuing to expand its portfolio and push the boundaries of nuclear medicine, Telix seeks to deliver life-changing therapies while driving sustainable growth.

TLX Intrinsic Value
16.51 AUD
Overvaluation 33%
Intrinsic Value
Price

See Also

What is Telix Pharmaceuticals Ltd's Operating Income?
Operating Income
17.6m AUD

Based on the financial report for Dec 31, 2023, Telix Pharmaceuticals Ltd's Operating Income amounts to 17.6m AUD.

Back to Top